SUNNYVALE, Calif., Nov. 7, 2017 /PRNewswire/ -- ClearLight Diagnostics, LLC (ClearLight), a developer of a next generationtissue processing and 3D imaging platform for cancer tissue, announced today that it has licensed additional technology from Stanford University. The new license agreement provides exclusive intellectual property rights covering inventions that can
"ClearLight continues to build its portfolio of valuable CLARITY related technology through in-licensing as well as our own internal work," said Sarah McCurdy, CEO of ClearLight. "The potential for our platform becomes stronger as we continually move forward with our internal product development program while enhancing our capabilities through the acquisition of additional, important IP."
About ClearLight Diagnostics
ClearLight Diagnostics is a technology development company focused on the discovery, development, and commercialization of innovative technologies to significantly improve the diagnosis and treatment of a wide range of diseases with an initial focus in oncology.
Founded by Karl Deisseroth M.D., Ph.D., ClearLight is developing an integrated instrumentation platform with the associated optimized biomarker panels based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is crosslinked to a three-dimensional network of hydrophilic polymers. The process produces a fully assembled, intact tissue, which is permeable to macromolecules and optically transparent, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and heterogeneous cellular interactions within the tumor microenvironment. This technology, paired with the development of a tissue imaging platform that includes the revolutionary microscopy method, COLM (CLARITY Optimized Light-sheet Microscopy) will enable unprecedented depth and acceleration of image collection from lipid-cleared samples interrogated with biomolecules.
Visit us at www.clearlightdx.com.
Contact: Sarah McCurdy, CEO email@example.com (510) 470-5042
View original content:http://www.prnewswire.com/news-releases/clearlight-diagnostics-licenses-exclusive-intellectual-property-rights-for-3d-visualization-image-processing-and-novel-clarity-based-tissue-clearing-instrumentation-300550042.html
SOURCE ClearLight Diagnostics
Subscribe to our Free Newsletters!
Abortion pills are used in the first trimester to terminate pregnancy. Women should be aware of ...
Tea tree oil is an essential oil derived from the leaves of the Melaleuca alternifolia plant and ...
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...View All